A unique integrated strategy and corporate and investment banking solution for global and emerging life science and healthcare companies.
The DNB Carnegie Back Bay Healthcare Partnership provides essential strategic and financial support to healthcare companies. We have a unique position bridging the Nordic and U.S. markets. Together, we provide a 360-degree understanding of healthcare corporate development, from chemistry to commercialization and raising capital to M&A as companies move through their lifecycle.
ABOUT THE PARTNERSHIP
The DNB Carnegie Back Bay Healthcare Partnership provides healthcare companies with strategic guidance, M&A and partnering support, and execution and capabilities in global capital markets and investment and commercial banking.
DNB, headquartered in Oslo, Norway, and Back Bay Life Science Advisors, headquartered in Boston, Massachusetts, are recognized leaders in banking and global life science development. Together, DNB Carnegie and Back Bay Life Science Advisors offer unique support to companies along the full continuum of life science and healthcare development.
The DNB Carnegie Back Bay Healthcare Partnership is comprised of dedicated multidisciplinary teams of healthcare experts and corporate and investment bankers who understand the complete picture of asset and company development.
Our combined expertise in healthcare and banking spans more than 110 years and 1,000 successful projects and transactions.
Learn more about the Partnership, subscribe for market insights, request an overview of our capabilities or connect with our advisors.
Analyst Reports
DNB Carnegie Back Bay publishes industry reports on the healthcare sector. Reports are authored by Back Bay Life Science Advisors’ experts on global life science development and DNB’s senior equity analysts.
Read our latest:
Nordic-American Healthcare Conference 2026
The Leading US-Nordic Healthcare Public Equity Investor Conference,
March 25-26, 2026 in New York City.
Hosted by DNB Carnegie Back Bay, this pre-eminent US-based Nordic healthcare equity investor event brings together US institutional healthcare investors and innovators with Nordic and US healthcare companies. LEARN MORE
STAY CONNECTED!
HEALTHCARE MARKETS UPDATE
NEWS & EVENTS
Learn more about the DNB Carnegie Back Bay Healthcare Partnership and subscribe to our weekly market overview for healthcare IPOs, licensing, venture, M&A, follow-on, and PIPE/RDO activity.
Nasdaq welcomed the DNB//Back Bay Partnership with a tribute on the Nasdaq Tower, May 2023, New York City.
-
DNB is Norway’s largest financial institution and leading corporate and investment bank, with international expertise in corporate banking and public capital markets across selected industry sectors, specializing in arranging financing for healthcare companies globally.
DNB has been established in North America since 1975, with a full-service branch in New York that serves corporate customers in the bank’s strategic business areas. A full range of wholesale investment banking services is provided by DNB Markets, Inc., a U.S. registered broker-dealer and wholly owned subsidiary of DNB Bank ASA in New York, established in 2003. Visit DNB Bank’s healthcare pages to learn more, here.
-
Back Bay Life Science Advisors (Back Bay) provides life science strategy and investment banking guidance and execution to global life science companies and their investors. Back Bay’s integrated strategy and banking teams advise companies on all aspects of life science, healthcare technology and drug development, including planning an initial concept, product commercialization, franchise growth, licensing, partnering, M&A, divestiture and more.
With a strong presence in Europe and the Nordic markets and a global reach, Back Bay has guided hundreds of healthcare companies through the complexities of commercial development and transactions. Every project and transaction is rooted in Back Bay’s deep expertise in life science, healthcare industry strategy and investment banking.
Matching strategic guidance, capital and transaction execution for global biopharma, medtech, healthtech and life science companies at every stage and sector
STRATEGIC ADVISORY
Franchise, business unit & therapeutic areas strategy
Healthcare and life
science product positioning and branding
Corporate growth
strategies
Liquidity and exit
planning
Healthcare transaction guidance and strategy
Due diligence and
valuation
Market analytics
MERGERS & ACQUISITIONS
Divestments
Licensing (buy and sell side)
Partnering
Mergers & acquisitions
Recapitalization
NewCo formation
Fairness opinion
FIXED INCOME ORIGINATION
Investment Grade Bonds
High yield bonds
Convertible bonds
US private placements
Debt and restructuring
advisory
EQUITY CAPITAL MARKETS
Franchise, business unit & therapeutic areas strategy
Healthcare and life science product positioning and branding
Corporate growth strategies
Liquidity and exit planning
Healthcare transaction guidance and strategy
Due diligence and valuation
Market analytics
ACQUISITION FINANCING
& LOAN ORIGINATION
Underwriting of acquisition debt
Bridge facilities
Revolving credit facilities
Commercial term loan
Institutional term loan
IPO financing
Debt advisory
TREASURY SOLUTIONS
Foreign exchange
Interest rate derivatives
Letters of credit & bank guarantees
Cash management
Working capital & trade finance
Electronic banking
Liquidity management
Check receivables and
payables
ACH, wires and global payments